Plus Therapeutics (PSTV) Equity Ratio (2016 - 2025)
Plus Therapeutics (PSTV) has disclosed Equity Ratio for 16 consecutive years, with 0.24 as the latest value for Q4 2025.
- Quarterly Equity Ratio rose 118.14% to 0.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.24 through Dec 2025, up 118.14% year-over-year, with the annual reading at 0.24 for FY2025, 118.14% up from the prior year.
- Equity Ratio for Q4 2025 was 0.24 at Plus Therapeutics, down from 0.27 in the prior quarter.
- The five-year high for Equity Ratio was 0.6 in Q1 2022, with the low at 1.96 in Q1 2025.
- Average Equity Ratio over 5 years is 0.04, with a median of 0.24 recorded in 2025.
- The sharpest move saw Equity Ratio soared 12697.65% in 2021, then crashed 1039.78% in 2024.
- Over 5 years, Equity Ratio stood at 0.6 in 2021, then crashed by 54.7% to 0.27 in 2022, then plummeted by 143.83% to 0.12 in 2023, then tumbled by 1039.78% to 1.35 in 2024, then surged by 118.14% to 0.24 in 2025.
- According to Business Quant data, Equity Ratio over the past three periods came in at 0.24, 0.27, and 0.29 for Q4 2025, Q3 2025, and Q2 2025 respectively.